Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 20/20 | 1.00 |
| ▸ | CTSK | P43235 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2075328 | 0.94 | CTSC (0.89) | CTSCCTSKKCNH2 | |
| SCHEMBL1499047 | 0.91 | CTSC (1.00) | CTSCCTSKKCNH2 | |
| SCHEMBL8032292 | 0.91 | CTSC (1.00) | CTSCCTSKKCNH2 | |
| SCHEMBL2073455 | 0.91 | CTSC (0.84) | CTSCCTSKKCNH2 | |
| SCHEMBL8039616 | 0.90 | CTSC (0.82) | CTSCCTSKKCNH2 | |
| SCHEMBL12422428 | 0.90 | CTSC (0.82) | CTSCCTSKKCNH2 | |
| SCHEMBL1499036 | 0.90 | CTSC (0.82) | CTSCCTSKKCNH2 | |
| SCHEMBL4396422 | 0.90 | CTSC (0.81) | CTSCCTSKKCNH2 | |
| SCHEMBL2074780 | 0.90 | CTSC (0.81) | CTSCCTSKKCNH2 | |
| SCHEMBL2074778 | 0.90 | CTSC (0.81) | CTSCCTSKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | claimed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | claimed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-10 | — | — | US | disclosed |
| US-11680049-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-13 | — | — | US | disclosed |
| US-11673872-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-13 | — | — | US | disclosed |
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20150210655-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2015-07-30 | — | — | US | disclosed |
| WO-2015110826-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2015-07-30 | — | — | WO | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673872-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 450/4885KCNH2 2478/4885 |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 432/4885KCNH2 2475/4885 |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 450/4885KCNH2 2478/4885 |
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885CTSK 3280/4885KCNH2 2084/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885CTSK 3280/4885KCNH2 2084/4885 |
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 432/4885KCNH2 2475/4885 |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 432/4885KCNH2 2475/4885 |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 432/4885KCNH2 2475/4885 |
| US-11680049-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 450/4885KCNH2 2478/4885 |
| US-20150210655-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CTSC 7/4885CTSK 432/4885KCNH2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.